For research use only. Not for therapeutic Use.
ST91 is a α2-adrenoceptor (α2AR) agonist. ST91 activates both α2AAR and non-α2AAR subtypes to produce spinal antinociception[1][2][3].
ST91 decreases the viability, proliferation and mitochondrial function of B16F10 cells[2].
ST91 (intrathecal administration) produces antinociception in rats[1].
| Catalog Number | I010594 |
| CAS Number | 4749-61-5 |
| Synonyms | N-(2,6-diethylphenyl)-4,5-dihydro-1H-imidazol-2-amine;hydrochloride |
| Molecular Formula | C13H20ClN3 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H19N3.ClH/c1-3-10-6-5-7-11(4-2)12(10)16-13-14-8-9-15-13;/h5-7H,3-4,8-9H2,1-2H3,(H2,14,15,16);1H |
| InChIKey | ZLRWFGBEDNTMEU-UHFFFAOYSA-N |
| SMILES | CCC1=C(C(=CC=C1)CC)NC2=NCCN2.Cl |
| Reference | [1]. Graham BA, et, al. Synergistic interactions between two alpha(2)-adrenoceptor agonists, dexmedetomidine and ST-91, in two substrains of Sprague-Dawley rats. Pain. 2000 Mar;85(1-2):135-43. [2]. Maccari S, et, al. α-Adrenoceptor stimulation attenuates melanoma growth in mice. Br J Pharmacol. 2022 Apr;179(7):1371-1383. [3]. Stone LS, et, al. ST91 [2-(2,6-diethylphenylamino)-2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional alpha-2A- or alpha-2C-adrenergic receptors. J Pharmacol Exp Ther. 2007 Dec;323(3):899-906. |
